Mohammad Amrollahi‐Sharifabadi
Mohammad Amrollahi‐Sharifabadi publishes mostly in Pharmacology, Genetics and Pharmacology, on topics such as Venomous Animal Envenomation and Studies, Drug-Induced Hepatotoxicity and Protection and Plant-based Medicinal Research.
- World rank
- #3,145,457 of 7,710,434 ranked researchers
- Rank in Iran
- #20,557 of 71,317
- Works
- 36
- Citations
- 318
- Citations per work
- 8.8
What does Mohammad Amrollahi‐Sharifabadi research?
Mohammad Amrollahi‐Sharifabadi's work is mostly in Pharmacology, Toxicology and Pharmaceutics (11%), Biochemistry, Genetics and Molecular Biology (7%), Medicine (6%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Everything else2363.7%
- Life Sciences821.6%
- Health Sciences25.9%
- Medicine25.9%
- Physical Sciences24.9%
- Materials Science24.9%
- Social Sciences13.9%
- Social Sciences13.9%
- 1Pharmacology11% of their works
- 2Genetics7% of their works
- 3Pharmacology6% of their works
- 4Materials Chemistry5% of their works
- 5Ecology, Evolution, Behavior and Systematics4% of their works
- 6Sociology and Political Science4% of their works
Research topics
- Venomous Animal Envenomation and Studies
- Drug-Induced Hepatotoxicity and Protection
- Plant-based Medicinal Research
- Botanical Research and Chemistry
- Atherosclerosis and Cardiovascular Diseases
- Graphene and Nanomaterials Applications
- Nanoparticles: synthesis and applications
- Inflammatory mediators and NSAID effects
Which keywords describe Mohammad Amrollahi‐Sharifabadi's research?
The keywords of their largest research topics: Toxicity, Inflammation, Nanomaterials, Drug-Induced Liver Injury, Envenoming, Hepatotoxicity, Snake Venom and Aconitum Alkaloids.
- Nanoparticles
- Immune Response
- Cyclooxygenase-2 Inhibitors
- Biomedical Applications
- Antimicrobial
- Aconitum Alkaloids
- Hepatotoxicity
- Drug-Induced Liver Injury
- Inflammation
- Toxicity
- Nanomaterials
- Envenoming
- Snake Venom
- Traditional Chinese Medicine
- Atherosclerosis
- Cancer
- Graphene
- Lupin Seeds
- Secondary Metabolites
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 19 words, with their numbers
- Toxicity103 topics
- Inflammation62 topics
- Nanomaterials62 topics
- Drug-Induced Liver Injury51 topic
- Envenoming51 topic
- Hepatotoxicity51 topic
- Snake Venom51 topic
- Aconitum Alkaloids41 topic
- Traditional Chinese Medicine41 topic
- Antimicrobial31 topic
- Atherosclerosis31 topic
- Biomedical Applications31 topic
- Cancer31 topic
- Cyclooxygenase-2 Inhibitors31 topic
- Graphene31 topic
- Immune Response31 topic
- Lupin Seeds31 topic
- Nanoparticles31 topic
- Secondary Metabolites31 topic
Where does Mohammad Amrollahi‐Sharifabadi work?
Mohammad Amrollahi‐Sharifabadi's main affiliation in the publication record is Lorestan University, Iran.
How many publications and citations does Mohammad Amrollahi‐Sharifabadi have?
OpenAlex counts 36 works and 318 citations for Mohammad Amrollahi‐Sharifabadi, an h-index of 8, ranking #3,145,457 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Mohammad Amrollahi‐Sharifabadi. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.